Retinal detachment occurs when fluid separates the retina (a thin, light sensing tissue) from its usual attachment at the back of the eye. If detached, these retinal cells lose their normal blood supply and begin to die, which is the primary cause of vision loss in retinal detachment. The 'macula' refers to the very centre of the retina, with the highest density of retinal cells, most responsible for vision. Significant vision loss occurs when this part of the retina becomes separated (termed a 'macula-off retinal detachment'). Typically, surgery is required to repair the retinal detachment.
Supporting the health of retinal cells at the macula may prolong their survival after detachment and their recovery postoperatively. Recent evidence has shown that boosting our nicotinamide adenine dinucleotide (NAD+) levels may improve the health of these cells and prolong their survival if detached. Oral Nicotinamide Riboside (NR) is converted into NAD+, and while not studied for macula-off retinal detachments, has been safely used in a range of other conditions. This study is designed to help evaluate the safety and tolerability of NR to help preserve vision in people diagnosed with macula-off retinal detachment.
This study drug is given as an oral supplement (tablet) at the time of retinal detachment diagnosis, and daily for 20 weeks thereafter. The drug aims to prolong survival of cells in the retina (and macula) and their recovery after surgery.
The long-term goal of this treatment is to reduce loss of vision after retinal detachment. The researchers will compare NR to a placebo (a look-alike substance that contains no drug) to see if NR has a positive effect on photoreceptor survival and quality of vision postoperatively.
NR has been approved by the Therapeutic Goods Administration in Australia for many purposes but has not been approved for use in retinal detachment treatment.

Start Date01 May 2025

Sponsor / Collaborator-

NCT06567717

/ Not yet recruitingPhase 2IIT

Feasibility of a Decentralized Double-Blind Randomized Controlled Trial of Zinc and Nicotinamide Riboside for the Treatment of Idiopathic Pulmonary Fibrosis

The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can treat iIPF. The main questions are:
Can the investigators recruit participants, and can participants complete study procedures without physically coming into specific clinical trial sites? Can people with IPF experience improvement in symptoms, quality of life, or functioning if they are take these supplements? The investigators will compare zinc and nicotinamide riboside to matched placebos (look-alike substances that contain no drug) to see if these supplements treat symptoms or lung function in people with IPF.
Participants will:
Take drug these supplements twice a day for 24 weeks. Complete pulmonary function testing and six minute walk tests with their own pulmonologists every 12 weeks. Complete a high resolution CT scan at the start and end of the study. Complete video study visits with the research team every 4 weeks. Complete surveys about their symptoms and the number of times they take the medication.

Start Date01 Jan 2025

Sponsor / Collaborator

Cedars-Sinai Health System

NCT04614714

/ RecruitingPhase 2/3IIT

Nicotinamide Riboside and Milk Production in the NICU

Breastfeeding has well-established immunity and developmental benefits for newborns, yet mothers of preterm infants often struggle to provide sufficient breast milk. The investigators hypothesize that supplementing mothers of preterm infants with nicotinamide riboside (NR) during early postpartum will result in increased milk production. NR is a unique precursor to NAD+, which functions in whole-body metabolism, including that which supports the elevated energy demands of lactation. In lactating rats, NR supplementation improved milk quantity and quality, with metabolic benefits for the mother and lasting protective advantages for the offspring. No studies have been conducted to date that explore the short- or long-term use of NR for increasing milk supply in lactating women. This study will follow a small cohort of women and very preterm infants in the NICU throughout two intervention phases-- one in which each mother will randomly receive either NR or a placebo, then the opposite treatment-- to determine the effect of maternal NR supplementation on expressed milk volume and other markers of metabolism.

Start Date01 Dec 2024

Sponsor / Collaborator

University of California, Davis

100 Clinical Results associated with Nicotinamide riboside

100 Translational Medicine associated with Nicotinamide riboside

100 Patents (Medical) associated with Nicotinamide riboside

955

Literatures (Medical) associated with Nicotinamide riboside

01 Jul 2025·MITOCHONDRION

Beneficial effects of mitophagy enhancers on amyloid beta-induced mitochondrial and synaptic toxicities in Alzheimer’s disease

Article

Author: Reddy, P Hemachandra ; Reddy, Arubala P ; Kshirsagar, Sudhir

The purpose of our study is to investigate the beneficial effects of mitophagy enhancers against mutant amyloid precursor protein (APP) and amyloid beta (Aβ) induced mitochondrial and synaptic toxicities in Alzheimer's disease (AD). Research spanning over two decades highlights the critical role of mitochondrial dysfunction and synaptic damage in the pathogenesis of both early-onset and late-onset AD. Emerging evidence suggests impaired clearance of damaged mitochondria is an early pathological event in AD, positioning mitophagy enhancers as potential therapeutic candidates. This study determined the optimal doses of four mitophagy enhancers-Urolithin A (UA), actinonin, tomatidine, and nicotinamide riboside (NR)-using immortalized mouse hippocampal (HT22) neurons. HT22 cells were transfected with mutant APP (mAPP) cDNA and treated with the enhancers. The effects were assessed by evaluating mRNA and protein expression levels of genes involved in mitochondrial dynamics, biogenesis, mitophagy, and synaptic function, alongside cell survival and mitochondrial respiration. Mitochondrial morphology was also examined in treated and untreated mAPP-HT22 cells. Results showed that mAPP-HT22 cells exhibited increased mitochondrial fission, reduced fusion, downregulated synaptic and mitophagy-related genes, diminished cell survival, impaired mitochondrial respiration, and excessively fragmented, shortened mitochondria. Treatment with mitophagy enhancers reversed these deficits, restoring mitochondrial and synaptic health. Enhanced cell survival, upregulation of mitochondrial fusion, synaptic, and mitophagy genes, improved mitochondrial structure, and reduced fragmentation were observed. Notably, UA demonstrated the most robust mitigating effects. These findings underscore the therapeutic potential of mitophagy enhancers, particularly UA, as promising candidates to treat mitochondrial and synaptic dysfunctions in AD.

01 May 2025·MEAT SCIENCE

Effects of nicotinamide riboside on stressed/fatigued barrow carcass characteristics and loin chop color stability

Article

Author: Hennesy, Hanna M ; Gonzalez, John M ; Xu, Xiaoxing ; Alambarrio, Daniela A ; Gravely, Morgan E ; Stelzleni, Alexander M ; Ellis, Olivia G

The objective of this study was to determine the effects of nicotinamide riboside (NR) supplementation on the color and color stability of fresh pork chops from barrows subjected to extreme stress/fatigue. One hundred barrows were supplemented 0, 15, 30, or 45 mg•hd^-1•kg body weight^-1 NR in feed, or 45 mg•hd^-1•kg body weight^-1 NR in an oral drench (DRE) 11 d prior to a stress/fatigue-inducing event and immediate harvest. Loins were collected, aged 10 days in vacuum bags, and chops were fabricated and used for an 8-day simulated retail display color-stability study. There were no treatment by day of display or treatment main effects for all color-related measures. There were day of display main effects for all color measures which indicated chops discolored in a typical manner. pH values indicated the current study's muscles were in an accelerated state of pH decline due to the extreme preharvest stress/fatigue-inducing event; however, NR supplementation was unable to elicit positive effects on color-stability measures.

07 Apr 2025·INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

Nicotinamide Riboside Mitigates Retinal Degeneration by Suppressing Damaged DNA-Stimulated Microglial Activation and STING-Mediated Pyroptosis

Article

Author: Jiang, Bing ; Duan, Peiyun ; Zhou, Yubing ; Wang, Cong ; Wang, Zewei ; Chen, Jiawei ; Zhang, Xian ; Jiang, Qian ; Tan, Guangshuang ; Zhu, Shanshan ; Tong, Ping ; Zhang, Lusi ; Liu, Jingyuan

Purpose:

Microglial activation plays a pivotal role in the pathogenesis of retinal degeneration, contributing to neuroinflammation within the retina. Previous studies identified that nicotinamide riboside (NR) mitigated light-induced retinal degeneration (LIRD) and inhibited microglial activation. The cGAS-STING signaling pathway has been recognized as a key mediator of inflammation in response to cellular stress and tissue damage. This study further explores the regulatory impact of NR on microglial activation and STING-mediated pyroptosis in retinal degeneration.

Methods:

Balb/c mice were subjected to bright light exposure to induce retinal degeneration. Bioinformatics analysis was used to identify the upregulated key genes and signaling pathways involved in the progression of retinal degeneration, based on mouse transcriptomes from the LIRD model. Molecular biology techniques and immunofluorescence staining were used to assess cGAS-STING activation and expression of pyroptosis-associated molecules. Retinal function, photoreceptor apoptosis and inflammatory response were evaluated in the presence and absence of NR supplementation.

Results:

Exposure to bright light resulted in mitochondrial dysfunction and the release of dsDNA, significantly triggering the activation of cGAS-STING pathway and microglial pyroptosis. In contrast, NR treatment preserved mitochondrial biosynthesis, inhibited STING expression in reactive microglia, and dampened the pro-inflammatory response. Additionally, intraperitoneal administration of the STING inhibitor H151 reduced light-induced microglial activation and pyroptosis, while improving retinal function and promoting photoreceptor survival.

Conclusions:

These findings suggest that NR confers neuroprotection by attenuating damaged DNA-triggered STING-mediated microglial activation and pyroptosis. Targeting the cGAS-STING pathway presents a promising therapeutic avenue for retinal degeneration.

News (Medical) associated with Nicotinamide riboside

04 Feb 2025

·www.prnewswire.com

NexGen Health Introduces Niagen Plus IV Therapy: Revolutionizing Cellular Health and Anti-Aging in Silicon Valley

NexGen Health in San Jose introduces Niagen Plus IV Therapy, an advanced treatment that boosts cellular health, enhances energy, and combats aging by replenishing NAD+ levels using nicotinamide riboside (NR). This innovative therapy complements NexGen Health's regenerative medicine offerings, setting a new standard for wellness in Silicon Valley. SAN JOSE, Calif., Feb. 4, 2025 /PRNewswire/ -- NexGen Health, Silicon Valley's premier destination for cutting-edge regenerative wellness, is proud to announce the launch of Niagen Plus IV Therapy, an innovative treatment designed to enhance cellular health, boost energy, and combat the effects of aging. This groundbreaking therapy harnesses the power of nicotinamide riboside (NR), a key precursor to NAD+ (Nicotinamide Adenine Dinucleotide), combined with IV delivery for optimal absorption and faster results. The Science Behind Niagen Plus IV Therapy Continue Reading NexGen Health NAD+ is a vital coenzyme found in all living cells, responsible for energy production, DNA repair, and cellular regeneration. As people age, NAD+ levels naturally decline, leading to fatigue, cognitive decline, and other age-related conditions. Niagen Plus IV Therapy replenishes NAD+ levels by delivering nicotinamide riboside (NR) directly into the bloodstream, bypassing the digestive system to ensure maximum efficacy and rapid cellular uptake. "Our Niagen Plus IV Therapy is a game-changer for patients seeking to improve energy levels, optimize cognitive function, and support overall longevity," said Ilbra Petros, Director of NexGen Health." This treatment is perfect for anyone looking to combat the cellular effects of aging and enhance their vitality." Key Benefits of Niagen Plus IV Therapy Cellular Regeneration: Restores NAD+ levels to support healthier, more resilient cells. Enhanced Energy: Improves mitochondrial function to combat fatigue and sustain energy throughout the day. Cognitive Performance: Boosts brain health, improving focus, memory, and overall mental clarity. Anti-Aging Effects: Supports DNA repair, reduces oxidative stress, and promotes healthy aging. Synergistic Wellness: Complements other treatments offered at NexGen Health, such as NAD therapy, peptides, and IV nutrient infusions. A New Standard of Care in Silicon Valley Located in the heart of San Jose, NexGen Health is renowned for its personalized, concierge-level wellness services. With the addition of Niagen Plus IV Therapy, NexGen Health continues to lead the way in advanced regenerative medicine, offering residents of Silicon Valley and beyond an opportunity to optimize their health at the cellular level. "Niagen Plus IV Therapy represents the future of anti-aging and wellness," added Ilbra. "We are thrilled to bring this innovative treatment to the Bay Area, providing our patients with a scientifically-backed solution to improve their quality of life and unlock their full potential." About NexGen Health NexGen Health is a state-of-the-art wellness center located in San Jose, CA, specializing in advanced regenerative medicine and innovative health solutions. From NAD therapy and peptide treatments to IV nutrient infusions and comprehensive wellness consultations, NexGen Health offers cutting-edge services tailored to individual patient needs. As a leader in cellular health and anti-aging therapies, NexGen Health combines the latest advancements in medical science with concierge-level care to deliver exceptional results. Schedule Your Niagen Plus IV Therapy Consultation Today To learn more about Niagen Plus IV Therapy or schedule a consultation, visit NexGen Health online at or call (408) 400-2967. Media Contact: Ilbra Petros NexGen Health 408-400-2967 [email protected] SOURCE NexGen Health WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

22 Nov 2024

·www.drugs.com

Could a Vitamin Be Effective Treatment for COPD?

FRIDAY, Nov. 22, 2024 -- A daily dose of vitamin B3 reduced inflammation in the lungs of patients with COPD , Danish researchers report. "This is significant, because inflammation can lead to reduced lung function in these patients," said researcher Morten Scheibye-Knudsen , of the University of Copenhagen. Patients with COPD -- the full name of which is chronic obstructive pulmonary disease -- are more likely to get pneumonia, influenza and other serious respiratory infections, which can be fatal. The new study included 40 participants with COPD and a control group of 20 healthy volunteers. They received either 2 grams a day of nicotinamide riboside -- a member of the vitamin B3 family -- or a placebo. After six weeks, researchers saw a 53% drop in a marker of inflammation known as interleukin 8, or IL 8. After 12 more weeks of vitamin therapy, the effect increased by 63%. "In other words," the researchers said in a university news release, "The group treated with vitamin B3 experienced reduced lung inflammation during the study." More study will be needed to confirm the findings and determine the long-term effect of nicotinamid riboside in treating COPD, Scheibye-Knudsen said. During the study, the team also observed that COPD patients have lower blood levels of a chemical called NAD, which appears to play a role in the aging process. NAD levels rose with vitamin B3 treatment and signs of cellular aging slowed, researchers reported Nov. 15 in the journal Nature Aging . "As we age, we seem to metabolize a molecule known as NAD," Scheibye-Knudsen said. "The loss of this molecule is also seen after DNA damage, for instance the type of damage associated with smoking." As such, he said NAD may be a target for future research and treatment. Meanwhile, his team plans a larger study to confirm the initial findings. "We hope this research will pave the way for new treatment options for COPD patients," Scheibye-Knudsen said. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

26 Sep 2024

·www.businesswire.com

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

LOS ANGELES--( BUSINESS WIRE )--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on healthy-aging research, today announced that Rob Fried, CEO of ChromaDex and Founder of Tru Niagen, will participate in a fireside chat moderated by Sean McGowan, Senior Analyst at Roth Capital Partners, at the Lytham Partners Fall 2024 Investor Conference. Wesley Yu, Vice President of Finance at ChromaDex, and Mr. Fried will also host virtual one-on-one meetings with investors. Company Webcast The webcasted fireside chat will take place at 1:15 PM ET on Tuesday, October 1, 2024. The webcast can be accessed at https://app.webinar.net/7yrd0odReoK or on the Company's website at chromadex.com. The webcast will also be available for replay following the event. 1x1 Meetings Mr. Fried and Mr. Yu will participate in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2024invreg . Further information on the conference is available at https://lythampartners.com/fall2024 . For additional information on ChromaDex, visit www.chromadex.com . About ChromaDex: ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, comprised of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality. Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available. Niagen is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen ® , the number one healthy-aging NAD+ supplement in the United States † . Clinically proven to increase NAD+ levels, Tru Niagen is helping people around the world transform the way they age (available at www.truniagen.com ). ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com , to which ChromaDex regularly publishes copies of its press releases, news, and financial information. † Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 3/1/2023-2/29/2024).

Oligonucleotide

100 Deals associated with Nicotinamide riboside

External Link

KEGG	Wiki	ATC	Drug Bank
-	Nicotinamide riboside	A11HA01	DB14933

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Corticobasal degeneration	Phase 2	Norway	Akershus Universitetssykehus HF	05 Mar 2024
Corticobasal degeneration	Phase 2	Norway	Oslo universitetssykehus HF	05 Mar 2024
Multiple System Atrophy	Phase 2	Norway	Oslo universitetssykehus HF	05 Mar 2024
Multiple System Atrophy	Phase 2	Norway	Akershus Universitetssykehus HF	05 Mar 2024
Parkinson Disease	Phase 2	Norway	Akershus Universitetssykehus HF	05 Mar 2024
Parkinson Disease	Phase 2	Norway	Oslo universitetssykehus HF	05 Mar 2024
Supranuclear Palsy, Progressive	Phase 2	Norway	Akershus Universitetssykehus HF	05 Mar 2024
Supranuclear Palsy, Progressive	Phase 2	Norway	Oslo universitetssykehus HF	05 Mar 2024
Cardiotoxicity	Phase 2	Norway	ChromaDex, Inc.	16 Mar 2023
Heart Failure	Phase 2	Norway	ChromaDex, Inc.	16 Mar 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03482167 (CTgov)	Phase 1/2	Mild cognitive disorder	64	Placebo (Placebo)	avsbahfape(xynhpzuquq) = ppvjhsjxfj zidvimaqfu (hmjnqlosrd, 4) View more	-	04 Apr 2025
				Niagen® (Nicotinamide Riboside)	avsbahfape(xynhpzuquq) = ffevzwzdcz zidvimaqfu (hmjnqlosrd, 4) View more
NCT03579693 (Pubmed \| Clin J Am Soc Nephrol)	Phase 2	Chronic Kidney Diseases	25	Coenzyme Q10	gluarzczqi(bzqamtzqvu) = qiobbghfhx iiuwnypemh (qopiohpqso, 0.04 - 7)	Positive	01 Mar 2025
NCT03743636 (NICE, CTgov)	Phase 3	Peripheral Arterial Disease	90	Nicotinamide riboside+Resveratrol (Nicotinamide Riboside + Resveratrol)	cnqhxtbqky(vszutuyprd) = uhfgeysoym iakvljekhq (dgexjfdzfk, 7.84) View more	-	14 Jan 2025
				Placebo+Nicotinamide riboside (Nicotinamide Riboside + Placebo)	cnqhxtbqky(vszutuyprd) = bofhreuaan iakvljekhq (dgexjfdzfk, 8.69) View more
NCT04990869 (Pubmed \| Nat Aging)	Not Applicable	Pulmonary Disease, Chronic Obstructive sputum interleukin-8 (IL-8)	40	Nicotinamide Riboside	pdwwsglmqf(pelxeqjcot) = snczawplcm tvkfysqiwx (zgeltjwrsn, -75.7 to -7.6)	Positive	15 Nov 2024
				Placebo	-
Biospace Manual	Phase 2	Peripheral Arterial Disease	90	Nicotinamide Riboside	rucrthjajw(kszaifobai) = dczvteiojt noplllskkx (efzrnadaff )	Positive	24 Jun 2024
				Nicotinamide Riboside combination with resveratrol	-
NCT03912220 (CTgov)	Phase 2	Small Fiber Neuropathy	45	Nicotinamide riboside (Nicotinamide Riboside)	qznzvzdwhz(dtdusilecx) = jthgwvuuuz dylgiplbdl (yssdcgfphl, niufjtkiyb - sjcaxhmsjc) View more	-	06 Jun 2024
				Placebo Oral Tablet (Placebo)	qznzvzdwhz(dtdusilecx) = edlbpajqqm dylgiplbdl (yssdcgfphl, roncitfzar - szhrrpqqfv) View more
NCT04112043 (CTgov)	Phase 1	Hypertension	147	Walking Exercise+Nicotinamide Riboside (NR) (NR Plus Walking Exercise)	sbegbyuvnl(bgezbeopox) = xcquandxfd tznxbbrzun (ifiixngsar, gyxuaschye - alqzhvuqvt) View more	-	06 Jun 2024
				Walking Exercise (Walking Exercise Plus Placebo)	sbegbyuvnl(bgezbeopox) = htgpaqwthj tznxbbrzun (ifiixngsar, mgtxxhqnul - euruxopyuk) View more
ATS2024	Not Applicable	Sepsis	-	Nicotinamide Riboside (NR) 30 mg/kg	maaltqcfph(hgjcpnlirw) = lfwxfjwvbv vkbywnmrwk (cpsrmadfzq )	-	19 May 2024
				H2O control	maaltqcfph(hgjcpnlirw) = chqfkppsgx vkbywnmrwk (cpsrmadfzq )
NCT03151707 (CTgov)	Phase 4	-	11	Nicotinamide Riboside	wmepqyeivv(llkffcsbji) = yisrshxyzr naubevguwc (qpvruycsgj, 0.025) View more	-	05 Mar 2024
NCT04818216 (NIRVANA, CTgov)	Phase 2	COVID-19 \| Acute Kidney Injury	28	Placebo (Placebo Group)	xsbhpuzdqz(zjbbkpwqnw) = fgnfqpvuid hezgliljus (kpnvydzdrr, 0.02) View more	-	26 Dec 2023
				Nicotinamide riboside (Nicotinamide Riboside Group)	xsbhpuzdqz(zjbbkpwqnw) = pwbcynqrft hezgliljus (kpnvydzdrr, .07) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Nicotinamide riboside

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation